Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Shares of Arcutis Biotherapeutics, Inc. (ARQT) have gained 2.3% over the past four weeks to close the last trading session at $13.40, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$19.88 indicates a potential upside of 48.4%.The average comprises eight short-term price targets ranging from a low of $15 to a high of$29, with a standard deviation of $4.22. While the lowest esti ...